Male hypogonadism and metabolic syndrome

Naifar, Manel; Rekik, N.; Messedi, Meriam; Chaabouni, Khansa; Lahiani, A.; Turki, Mouna; Abid, M.; Ayedi, Fatma; Jamoussi, Kamel

doi:10.1111/and.12305

Cited by 23 publications

(16 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As shown in Table 1, a considerable body of literature exists demonstrating a bidirectional link between TD and Met S [23441424344454647484950515253545556575859606162]. Several systematic reviews, crosssectional studies, and clinical trials have reported low levels of total T (TT) and sex-hormone binding globulin (SHBG) in men with Met S, irrespective of age [11446364].…”

Section: Introductionmentioning

confidence: 99%

Impact of Testosterone Deficiency and Testosterone Therapy on Lower Urinary Tract Symptoms in Men with Metabolic Syndrome

Traish

Johansen

2018

World J Mens Health

View full text Add to dashboard Cite

Lower urinary tract function is modulated by neural, vascular and urethral and bladder structural elements. The pathophysiological mechanisms of lower urinary tract symptoms (LUTS) encompass prostate enlargement, alterations in urethra histological structure bladder fibrosis and alterations in pelvic neuronal and vascular networks, The complex pathophysiological relationship between testosterone (T) deficiency (TD) and the constellations LUTS, and metabolic dysfunction manifested in the metabolic syndrome (Met S) remains poorly understood. TD has emerged as one the potential targets by which Met S may contribute to the onset and development as well as worsening of LUTS. Because it has been recognized that treatment of men with Met S with T therapy ameliorates Met S components, it is postulated that T therapy may represent a therapeutic target in improving LUTS. Furthermore, the effect of TD on the prostate remains unclear, and often debatable. It is believed that T exclusively promotes prostate growth, however recent evidence has strongly contradicted this belief. The true relationship between benign prostatic hyperplasia, TD, and LUTS remains elusive and further research will be required to clarify the role of T in both benign prostatic hypertrophy (BPH) and LUTS as a whole. Although there is conflicting evidence about the benefits of T therapy in men with BPH and LUTS, the current body of literature supports the safety of using this therapy in men with enlarged prostate. As the population afflicted with obesity epidemic continues to age, the number of men suffering from Met S and LUTS together is expected to increase.

show abstract

Section: Introductionmentioning

confidence: 99%

Impact of Testosterone Deficiency and Testosterone Therapy on Lower Urinary Tract Symptoms in Men with Metabolic Syndrome

Traish

Johansen

2018

World J Mens Health

View full text Add to dashboard Cite

show abstract

“…ADT for the treatment of PCa also induces dyslipidaemia (181, 182, 183), while T replacement therapy in hypogonadal men exhibits beneficial effects on the lipid profile (127, 184, 185). An inverse correlation exists between serum T and high-sensitive C-reactive protein in normal ageing (186) and hypogonadal (187) men, and T replacement has been shown to shift the cytokine balance towards a state of reduced inflammation (184, 188). …”

Section: Cardiovascular Risk and Male And Female Androgen Statusmentioning

confidence: 99%

MECHANISMS IN ENDOCRINOLOGY: The sexually dimorphic role of androgens in human metabolic disease

Schiffer

Kempegowda

Arlt

et al. 2017

European Journal of Endocrinology

118

View full text Add to dashboard Cite

Female androgen excess and male androgen deficiency manifest with an overlapping adverse metabolic phenotype, including abdominal obesity, insulin resistance, type 2 diabetes mellitus, non-alcoholic fatty liver disease and an increased risk of cardiovascular disease. Here, we review the impact of androgens on metabolic target tissues in an attempt to unravel the complex mechanistic links with metabolic dysfunction; we also evaluate clinical studies examining the associations between metabolic disease and disorders of androgen metabolism in men and women. We conceptualise that an equilibrium between androgen effects on adipose tissue and skeletal muscle underpins the metabolic phenotype observed in female androgen excess and male androgen deficiency. Androgens induce adipose tissue dysfunction, with effects on lipid metabolism, insulin resistance and fat mass expansion, while anabolic effects on skeletal muscle may confer metabolic benefits. We hypothesise that serum androgen concentrations observed in female androgen excess and male hypogonadism are metabolically disadvantageous, promoting adipose and liver lipid accumulation, central fat mass expansion and insulin resistance.

show abstract

“…Many changes are described with important sexual symptoms, similar to the presence of overt hypogonadism, with important diseases linked to this testosterone deficiency: bone demineralization [16], increased cardiovascular risk [17], frailty [18], weight gain [19], dyslipidemia [20] and increased general mortality [21][22][23].…”

Section: Sexual Dysfunction 36mentioning

confidence: 99%

Hypogonadism in Male Sexual Dysfunction

Stoian¹,

Mozoş²,

Craina³

et al. 2017

Sexual Dysfunction

View full text Add to dashboard Cite

Normal testosterone level is influencing all the steps of the male psychosexual development: intrauterine neonatal and final psychosexual development.. At pubertal stage, the quality of testosterone secretion is conditioning the development of the mature male phenotype. In adult life, eugonadism sustains desire, arousal, determines spontaneous erections, facilitates stimulated erection, influencing the response rate to medication. Moreover, eugonadism sustain daydreaming and phantasies, both needed for a normal sexual life. The pathogenic mechanism of all these actions is presented. Talking about hypogonadism means not only the classical types of hypogonadism: due to classical testicular disease of central, hypothalamic and hypophysis disease, but also the partial testosterone deficiency induces by aging (late onset hypogonadism), weight increase (up to 30% of males with metabolic syndrome and 50% of males with diabetes) or secondary hypogonadism described in chronic use of steroids or after long exposure to stress, especially in young males. All these types of hypogonadism, that affect young, middle aged or old males will be presented separately. A therapeutic approach that is individualized for each type of hypogonadism, should consider positive and possible negative effects and all alternatives will be presented: life style changes, sustained weight loss, increase exercise, supplemental therapy, pro fertility treatment.

show abstract

Male hypogonadism and metabolic syndrome

Cited by 23 publications

References 51 publications

Impact of Testosterone Deficiency and Testosterone Therapy on Lower Urinary Tract Symptoms in Men with Metabolic Syndrome

Impact of Testosterone Deficiency and Testosterone Therapy on Lower Urinary Tract Symptoms in Men with Metabolic Syndrome

MECHANISMS IN ENDOCRINOLOGY: The sexually dimorphic role of androgens in human metabolic disease

Hypogonadism in Male Sexual Dysfunction

Contact Info

Product

Resources

About